Emerging Therapies for Congestive Heart Failure.

Published

Journal Article (Review)

The treatment of atherosclerotic heart disease has improved remarkably over the last several decades; however, the outlook for patients with symptomatic congestive heart failure with reduced ejection fraction remains bleak. Current drug therapies target the neurohormonal activation that accompanies congestive heart failure, but do not address the fundamental pathology inherent in this condition-the loss of contractile capacity. Stem cell therapies offer the possibility of rectifying this deficiency and normalizing left ventricular dimensions and cardiac performance by regenerating novel contractile tissue, thereby reversing the negative remodeling that portends progressive left ventricular dysfunction, worsening symptoms, and ultimately cardiogenic shock. Here we review the promise of stem cell therapies in the treatment of heart failure with reduced ejection fraction, the current state of clinical developments, and briefly comment on the future of the field.

Full Text

Duke Authors

Cited Authors

  • Povsic, TJ

Published Date

  • January 2018

Published In

Volume / Issue

  • 103 / 1

Start / End Page

  • 77 - 87

PubMed ID

  • 29044498

Pubmed Central ID

  • 29044498

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1002/cpt.913

Language

  • eng

Conference Location

  • United States